BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38622869)

  • 21. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
    Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR.
    Park CK; Oh HJ; Kim YC; Kim YH; Ahn SJ; Jeong WG; Lee JY; Lee JC; Choi CM; Ji W; Song SY; Choi J; Lee SY; Kim H; Lee SY; Park J; Yoon SH; Joo JH; Oh IJ
    J Thorac Oncol; 2023 Aug; 18(8):1042-1054. PubMed ID: 37085032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
    Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
    Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
    Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
    Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
    ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience.
    Vrankar M; Stanic K; Jelercic S; Ciric E; Vodusek AL; But-Hadzic J
    Radiol Oncol; 2021 Nov; 55(4):482-490. PubMed ID: 34821136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
    Moore S; Leung B; Wu J; Ho C
    J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.
    Jazieh AR; Onal HC; Tan DS; Soo RA; Prabhash K; Kumar A; Huggenberger R; Cho BC
    Ther Adv Med Oncol; 2022; 14():17588359221122720. PubMed ID: 36119641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
    Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting.
    Waterhouse D; Yong C; Frankart A; Brannman L; Mulrooney T; Robert N; Aguilar KM; Ndukum J; Cotarla I
    Future Oncol; 2023 Sep; 19(28):1905-1916. PubMed ID: 37497677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
    Tsuji K; Mizugaki H; Yokoo K; Kobayashi M; Kawashima Y; Kimura N; Yokouchi H; Kikuchi H; Sumi T; Kawai Y; Kobashi K; Morita R; Ito K; Kitamura Y; Minemura H; Nakamura K; Aso M; Honjo O; Tanaka H; Takashina T; Tsurumi K; Sugisaka J; Tsukita Y; Konno S; Oizumi S
    Cancer Sci; 2024 Apr; 115(4):1273-1282. PubMed ID: 38287788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
    Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
    J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.
    Joosten PJM; Dickhoff C; van der Noort V; Smeekens M; Numan RC; Klomp HM; van Diessen JNA; Belderbos JSA; Smit EF; Monkhorst K; Oosterhuis JWA; van den Heuvel MM; Dahele M; Hartemink KJ
    Interact Cardiovasc Thorac Surg; 2022 Mar; 34(4):566-575. PubMed ID: 34734237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.
    Provencio M; Carcereny E; López Castro R; Calvo V; Rodríguez Abreu D; Cobo M; Ortega AL; Bernabé R; Guirado M; Massutí B; Del Barco-Morillo E; Bosch-Barrera J; Camps C; Carroll R; Rault C; Chaib C; Penrod J; Vo L; Ralphs E; Daumont MJ
    Transl Lung Cancer Res; 2023 Oct; 12(10):2113-2128. PubMed ID: 38025806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
    Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
    Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.